INDIA | CHEMICALS | COVERAGE INITIATION



Tatva Chintan Pharma Chem

A BREATH OF FRESH AIR



A play on tightening emission norms Revenue/PAT CAGR expected at 34%/41% over FY21-24E Initiate with BUY & TP of INR 2,650/share, implying 26% upside



TABLE OF CONTENTS

Introduction	3
Focus Charts	4
Investment Thesis	5
SDA demand likely to get a further boost	7
Technocrat promoters with a strong focus on R&D	9
Financials	10
Company Background	12
Industry overview	15
Raw Materials	21
Manufacturing Facilities	22
Valuation	23
Key Risks	23
Board of Directors	25
Financial Tables	27



TCPL's Structure directing agents (SDAs) are made using the electrolysis process, which is considered to be green. Given the functionally critical nature of SDAs from customers' perspective, there is a strong barrier to entry (customer approval takes ~5-7 years) and high degree of customer stickiness. Due to further tightening of environmental norms and further applications, demand for SDAs is likely to get a further boost. Being the only commercial manufacturer out of India and second largest in the world for SDAs, we believe TCPL is well placed to benefit from this shift.

RECENT REPORTS



JM Financial Institutional Securities Limited

JM FINANCIAL

Tatva Chintan Pharma Chem A Breath of Fresh Air

Tatva Chintan Pharma Chem Limited (TCPL) operates through 2 manufacturing facilities - Ankleshwar and Dahej - in Gujarat. TCPL is the largest and only commercial manufacturer of structure directing agents (SDAs) for zeolites in India and the second largest globally.

In addition, TCPL is also one of the leading global producers of an entire range of phase transfer catalysts (PTCs) in India and one of the key producers globally. TCPL's customers include Merck, Bayer, Asian Paints, Laurus Labs, Tosoh Asia, SRF, Navin Fluorine, among others. In FY19, FY20, and FY21, revenue generated from its top 10 customers represented 47%, 58%, and 60% of revenue from operations, respectively.

TCPL is currently in the process of further expansion at its Dahej facility. Plant testing and commissioning would start from Oct'22 while the commercial production is expected to commence in Nov'22. Hence, we expect the full ramp-up of additional capacities to start from 4QFY23.

We forecast Sales, EBITDA and EPS to post 34%, 44%, and 41% CAGR, respectively, over FY21-24E. Moreover, we expect its ROCE (pre-tax) to show continuous improvement and reach ~31% by FY24E. We initiate coverage on TCPL with a BUY rating and Mar'23 TP of INR 2,650/share (based on 40X Mar'24E EPS), implying 26% upside. Key risks: High dependency on R&D and introduction of innovative products, dependency on a limited number of customers and suppliers of certain raw materials.

Play on tightening emission norms: TCPL's SDAs are made using the electrolysis process, which is considered to be clean and green. Given the functionally critical nature of SDAs from customers' perspective, there is a strong barrier to entry (customer approval takes 5-7 years) and high degree of customer stickiness. The advanced chemistries also make it extremely difficult for new players to enter the market. These SDAs are used to control NOx emissions. Declining permissible NOx emissions limits could further boost SDA demand resulting in higher per vehicle usage of SDAs.

Revenue/EBITDA/PAT CAGR expected at 34%/44%/41% over FY21-24E: We expect TCPL's revenues to register a 34% CAGR over FY21-24E and reach INR 7.1bn by FY24E on the back of ramp-up of additional available capacities from i) expansions taken at Dahej in FY20 and ii) further expansion in FY22. The additional capacities should largely cater to the increasing demand of SDAs as SDA contribution would rise from INR 1.2bn in FY21 (40% of overall revenue) to INR 5.0bn in FY23E (69% of overall revenue). Due to a jump in SDA contribution and positive operating leverage, EBITDA margins are slated to rise from 21.9% in FY21 to 27% in FY24E. As a result, its EBITDA is likely to reach INR 2.0bn (a 44% CAGR over FY21-24E) and PAT is likely to reach INR 1.5bn (a 41% CAGR over FY21-24E).

Initiate with BUY and TP of INR 2,650 per share: Due to further tightening of environmental norms and further applications, demand for SDAs is likely to get a further boost. Being the only commercial manufacturer out of India and second largest in the world for SDA, we believe TCPL is well placed to benefit from this shift. We initiate coverage on TCPL with a BUY and Mar'23 TP of INR 2,650/share (based on 40X Mar'24E EPS). We believe TCPL's valuation premium (compared with other listed Indian specialty chemicals companies) is justified due to strong entry barriers offered by SDAs.

Recommendation and Price Target	
Current Reco	BU
Current Price Target (12M)	2,65
Upside (%)	26

Key Data – TATVA IN	
Current Market Price	INR2,105
Market cap (bn)	INR46.7/US\$0.6
Free Float	20%
Shares in issue (mn)	20.1
Diluted share (mn)	22.2
52-week range	2,534/2,001
Sensex/Nifty	61,260/18,267
INR/US\$	74.9

Price Performar	nce		
%	1M	6M	12M
Absolute	0.6	0.0	0.0
Relative*	-3.1	0.0	0.0

Financial Summary					(INR mn)
Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
Net Sales	2,632	3,004	4,182	5,617	7,151
Sales Growth (%)	27.6	14.1	39.2	34.3	27.3
EBITDA	550	657	1,015	1,492	1,957
EBITDA Margin (%)	20.9	21.9	24.3	26.6	27.4
Adjusted Net Profit	378	523	859	1,136	1,476
Diluted EPS (INR)	18.8	26.0	38.8	51.2	66.6
Diluted EPS Growth (%)	90.9	38.3	49.0	32.1	30.0
ROIC (%)	24.8	24.0	26.7	24.2	26.0
ROE (%)	38.3	36.8	27.0	21.7	22.9
P/E (x)	111.9	80.9	54.3	41.1	31.6
P/B (x)	35.9	25.5	9.9	8.1	6.6
EV/EBITDA (x)	77.9	65.2	40.7	27.9	20.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0

JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet & Visible Alpha

You can also access our portal: www.imflresearch.com


Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

 Krishan Parwani	Dayanand Mittal	We acknowledge the support
krishan.parwani@jmfl.com	dayanand.mittal@jmfl.com	of Prashanth Kamath in the
Tel: (91 96) 62095500	Tel: (91 96) 19388870	preparation of this report


*To the BSE Sensex

Focus charts

Exhibit 1. TCPL's revenues likely to register 34% CAGR over FY21-24E



Source: Company, JM Financial



Source: Company, JM Financial





Exhibit 2. Export contribution to rise to ~88% of overall sales




Source: Company, JM Financial





Source: Company, JM Financial

Exhibit 6. RoCE (pre-tax) to gradually improve to ~31% by FY24E



Source: Company, JM Financial

Source: Company , JM Financial

Investment Thesis

TCPL's vigorous focus on R&D has enabled the company to make highly complex structure directing agents (SDAs). These SDAs are used to control NOx emissions and are manufactured using the electrolysis process, which generates minimal waste/by-products. Due to tightening of environmental norms and growing applications, demand for SDAs is likely to get a further boost. Being the only commercial manufacturer from India and the second largest in the world for SDAs, we believe TCPL is well-placed to benefit from this shift. We expect TCPL's Revenue/EBITDA/PAT to post a CAGR of 34%/44%/41% over FY21-24E on the back of a ramp-up in additional available capacities at its Dahej facility and jump in EBITDA margins, led by rising SDA contribution to the top line. We initiate coverage on TCPL with a BUY rating and Mar'23 TP of INR 2,650/share (based on 40X Mar'24E EPS). We believe TCPL's valuation premium (compared with other listed Indian specialty chemicals companies) is justified due to the strong entry barriers offered by SDAs.


- Leading manufacturer of SDA and PTCs with a focus on 'green' chemistry processes: TCPL currently operates through 2 manufacturing facilities - Ankleshwar and Dahej - in Gujarat. TCPL is the largest and only commercial manufacturer of SDAs for zeolites in India and the second largest globally. TCPL is also one of the leading global producers of an entire range of PTCs in India and one of the key producers globally. As part of the manufacturing processes, TCPL has adopted various green chemistry processes, including electrolysis. Besides the single starting raw material, electrolysis uses water and electricity to produce the final product. As a result, there is minimal generation of waste or byproducts.
- SDAs offer strong entry barriers: TCPL's SDAs (40% of FY21 revenues) are a forward integration of PTCs and are made using the electrolysis process, which is considered to be clean and green. These SDAs are used to manufacture zeolites, which are further used as catalysts in catalytic converters (a mechanical device) to stop emission of polluting gases from automobiles, marines, refineries, industrial chimneys, etc. Given the functionally critical nature of SDAs from customers' perspective, there is a strong barrier to entry (customer approval takes ~5-7 years) and high degree of customer stickiness. TCPL started manufacturing SDA in 2011 but the major contribution started from FY20, likely on account of customer approvals. The advanced chemistries also make it extremely difficult for new players to enter the market.
- Only commercial manufacturer of SDAs for zeolites in India: Currently, only a handful players manufacture SDAs for zeolite across the globe. The underlying reason for that is the long approval process combined with a high degree of specificity of the product and electrolysis process. Currently, SACHEM is the world's largest player for SDAs for zeolite and TCPL is the second largest player with a ~12% volume market share (per industry estimates, global market for SDA used in zeolites was 12,000MT in FY21). Both these players manufacture SDAs using the electrolysis process. In our view, TCPL has been able to take away market share from SACHEM as it provides the catalyst manufacturers some diversity. Moreover, SACHEM's China plant is located in Jiangsu province, which currently is in the red zone (facing a power crisis). This could possibly disrupt its supplies. We believe this could further help TCPL procure additional orders.
- Huge growth in SDA led by new customer approvals: TCPL received two key client approvals in 2018 (Tosoh Asia) and in early 2019 (Weihai PIDC new materials); this has led to a sharp rise in SDA sales from INR 254mn in FY19 (or 12% of overall revenue) to INR 1,202mn in FY21 (or 40% of overall revenue). Sales contribution from Tosoh Asia increased from 1% in FY19 to 17% while that of Weihai PIDC increased from 2% in FY19 to 15% in FY21. Further, strong sales growth in TCPL's SDA is expected to continue (60% FY21-24 CAGR) and hence its share in total revenue is expected to rise to 65-70% in next 2-3 years. As per industry sources, current SDA demand is 12,000MT, which is likely to rise to 24,000MT over the next 3-4 years on account of Euro/BS-6 while there would be incremental demand of ~10,000MT on account of Euro/BS-7. Hence, total SDA demand is likely to reach 34,000MT by FY25E. We believe that TCPL could increase its

market share in SDA to ~19% by FY25E (vs. ~12% in FY21), by on-boarding new zeolite manufacturers and supplying additional quantities to existing customers.

- Offers a wide range of phase transfer catalysts (PTCs): PTCs (27% of FY21 revenue) are used for a variety of industrial processes and facilitate the migration of a reactant from one phase into another, which is where the reaction occurs in a heterogeneous multiphase system. Phase transfer catalysts are extensively used by the pharmaceuticals industry for synthesis, R&D, formulation and laboratory applications. For example, if a pharma company is making a tablet of a compound and wants to make a syrup of the same compound, it either will have to use heating or solvents. However, using these steps could increase one step and in turn one would have to incur additional expenses. Moreover, there lies a risk of cross-contamination. Hence, to avoid this, PTCs are used to save costs and improve yields in the pharma industry. In the agrochemicals industry, PTCs promote herbicide production in an efficient manner with improved purity. Over FY21-24E, PTC segment revenues are likely to register a modest 2% CAGR as the company wants to focus on SDAs.
- Pharmaceutical, agrochemical intermediates and other specialty chemicals (PASC) to provide secondary growth: TCPL received FDA approval from Gujarat State for the manufacture of cetrimide and cetyl pyridinium chloride in 2004; this allowed it to expand its market in this portfolio. Under the PASC segment, in FY21, TCPL manufactured 53 products of various categories such as glymes, pyridinium salts, epoxy resins and specialty amines. The global glymes market is expected to post a 15-17% CAGR over CY20-25E. For Glymes, TCPL is the largest producer from India and one of the largest across the globe. We believe TCPL's market positioning and product offerings across different segments could act as catalysts for secondary growth and we estimate TCPL's PASC segment revenues to register a healthy 11% CAGR over FY21-24E. We believe there could be an upside risk to our growth estimate for this segment after recent disruptions in China as adoption of the China+1 strategy intensifies.

SDA demand likely to get a further boost

Zeolites are more efficient for use in catalytic converters: Diesel catalytic converters are exposed to frequent temperature changes; however, they must remain stable for the entire life of the vehicle. The key benefit of using the zeolite catalyst is that it retains much more of its original structure than other diesel catalyst formulations (click here and here). Hence, demand for zeolite catalysts is likely to expand due to a) further tightening of automobile gas exhaust emission regulations in CY20-25 in China/India, b) possible usage for adsorption of volatile organic compounds and c) NOx emission reduction in Nitric acid plants (click here).




Source: Tosoh, JM Financial

TOSOH

Exhibit 8. Demand for zeolite catalysts likely to continue to increase further due to tightening of emission regulations


6-5. Business Strategies: Advanced Materials (High-silica zeolite)



Source: Tosoh, JM Financial

Limited threat to SDA demand from rising adoption of Electric Vehicles: TCPL's SDAs are used to control the polluting gases from automobiles (~75% of TCPL's SDA volume), refineries, industries, etc. Typical passenger vehicle would require ~100g of SDAs, while commercial vehicles would require ~5kg of SDAs. Hence, major usage of TCPL's SDAs would be towards the heavy vehicles, marines, etc. Moreover, adoption of electrical commercial vehicles is still a distant possibility. Further, as seen in Exhibit 9, permissible NOx emission limits have continuously declined and is likely to decline even further in the remaining internal combustion engine fleet. Hence, SDA demand could probably be boosted further on account of stringent norms requiring even lower emissions, resulting in higher per vehicle usage of SDAs.

Exhibit 9. Permissible NOx emissions limit have continuously declined



Source: International Council of Clean Transportation, JM Financial



	*2	*1	*1	۲							
		HDD (g/kwh)									
Norm	NS V	NS VIa	NS VIb	BS VI	EU VI						
co	4.0	4.0	4.0	4.0	4.0						
HC	0.55	0.16	0.16	0.16	0.16						
NOx	2	0.46	0.46	0.46	0.46						
NH ₃	25ppm	10ppm	10ppm	10ppm	10ppm						
PM	0.03	0.01	0.01	0.01	0.01						
PN	-	6x10 ¹¹	6x10 ¹¹	6x10 ¹¹	6x1011						
Cycle	ETC	WHTC	WHTC	WHTC	WHTC						

Source: BASF, JM Financial


Exhibit 11. Off-road vehicles permissible emission limits

	*1	۲							
	Off-F	Road (g/k	wh) (56-	129kw ra	inge)				
Norm	NS IV	Trem IV	US T4F	EU IV	EU V				
со	5.0	5.0	5.0	5.0	5.0				
HC	0.19	0.19	0.19	0.19	0.19				
NOx	3.3	0.4	0.4	0.4	0.4				
PM	0.025	0.025	0.02	0.025	0.015				
PN	5x1012	-	-	-	1x10 ¹²				
Cycle	NRTC	NRTC	NRTC	NRTC	NRTC				

Source: BASF, JM Financial


Technocrat promoters with a strong focus on R&D

R&D efforts focused on development of new products: TCPL has a high focus on R&D and its R&D spends as a % of sales has been 1.5-2.0% over FY19-21. This is comparable to listed large chemical companies in India. Its R&D capabilities have enabled it to expand its offerings from 72 products as at Mar'11 to more than 154 products as at Mar'21. TCPL's R&D team consists of 20 people, of which 7 have PhDs. This team is headed by one of the promoters, Mr. Chintan Shah.



Source: Company, JM Financial

Ongoing capacity expansions driving the growth: Over FY19-21, TCPL phase-wise increased its reactor capacity to 280KL in FY21 (from 160KL in FY19) and assembly lines were increased to 17 in FY21 (from 10 in FY19). The company is currently in the process of further expansion at its Dahej facility. Plant testing and commissioning would start from Oct'22 while the commercial production is expected to commence in Nov'22. Hence, we expect the full ramp-up of additional capacities to start from 4QFY23.




Source: Company, JM Financial

Source: Company, JM Financial

Strong technocrat promoters: TCPL is led by Chintan Shah (B.Engg, computer science, MS university, Baroda), Shekhar Somani (B.Pharm, MS university, Baroda), and Ajay Patel (B.Engg, chemical, MS university, Baroda), who have over 24-26 years of experience in the chemicals industry.

Financials

- Expect Revenue/EBITDA/PAT CAGR of 34%/44%/41% over FY21-24E: We expect TCPL's revenues to register a 34% CAGR over FY21-24E and reach INR 7.1bn by FY24E on the back of ramp-up of additional available capacities from i) expansions taken at Dahej in FY20 and ii) further expansion in FY22. The additional capacities should largely cater to the increasing demand of SDAs as SDA contribution would rise from INR 1.2bn in FY21 (40% of overall revenue) to INR 5.0bn in FY23E (69% of overall revenue). Due to a jump in SDA contribution and positive operating leverage, EBITDA margins are slated to rise from 21.9% in FY21 to 27% in FY24E. As a result, its EBITDA is likely to reach INR 2.0bn (a 44% CAGR over FY21-24E) and PAT is likely to reach INR 1.5bn (a 41% CAGR over FY21-24E).
- Exports contribution to inch up to ~88% of overall sales: TCPL's customers include Merck, Bayer, Asian Paints, Laurus Labs, Tosoh Asia, SRF, Navin Fluorine, among others. In FY19, FY20, and FY21, revenue generated from its top 10 customers represented 47%, 58.4%, and 60% of revenue from operations, respectively. TCPL exports its products to over 25 countries. In FY21, exports to Germany, US, and China accounted for 1.4%, 14.8%, and 17.9%, respectively. Since TCPL's SDAs are primarily exported, its exports are likely to inch up to ~88% of overall sales in FY22-24E.
- ROCE (pre-tax) to show continuous improvement and reach ~31% by FY24E: Due to the shift towards high margin SDAs, TCPL's EBITDA margins are likely to jump to 26-27% in FY23-24E (vs. 21-22% in FY20-21). Further, its gross fixed asset turns are likely to reach the normalised 2.1x by FY24E post ramp-up of additional capacities. As a result, TCPL's ROCE (pre-tax) is likely to show continuous improvement and reach ~31% by FY24E.



Source: Company, JM Financial

Source: Company, JM Financial

Exhibit 17. TCPL's EBITDA is likely to post a 44% CAGR over FY21-24E





Exhibit 18. TCPL's PAT is likely to register a 41% CAGR over FY21-24E



Source: Company, JM Financial







Exhibit 20. RoCE (pre-tax) to gradually improve to ~31% by FY24E



Source: Company , JM Financial

Source: Company , JM Financial

Company Background

TCPL is a specialty chemicals manufacturing company which was incorporated in 1996, and currently operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat. TCPL is engaged in the manufacture of a diverse portfolio of structure directing agents ("SDAs"), phase transfer catalysts ("PTCs"), electrolyte salts for super capacitor batteries and pharmaceutical & agrochemical intermediates and other specialty chemicals. TCPL is the largest and only commercial manufacturer of SDAs for zeolites in India. It also holds the second largest position globally.

In addition, TCPL is one of the leading global producers of an entire range of PTCs in India, and one of the key producers across the globe. As a manufacturer of specialty chemicals, the company focuses on application of its products, which form a key ingredient to its customers' manufacturing and industrial processes.

TCPL's customers include Merck, Bayer AG, Asian Paints, Ipox Chemicals, Laurus Labs, Tosoh Asia, SRF Limited, Navin Fluorine, Oriental Aromatics, Atul Limited, Otsuka Chemical, Meghmani Organics Limited, Divi's Laboratories Limited, Hawks Chemical Company Limited, Firmenich Aromatics, Jiangsu Guotai Super Power, New Materials, and Jade Chem. Apart from its customers in India, the company also exports its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK. Its exports accounted for 64.9%, 69.6%, 76.7% and 70.6%, of its revenue from operations, during FY18, FY19, FY20 and FY21, respectively.

Exhibit 21. Ke	ey events in the history of TCPL
Calendar year	Particulars
1996	Incorporation of the Company
2004	Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at its Ankleshwar Manufacturing Facility
2007	Expansion of manufacturing capacity at its Ankleshwar Manufacturing Facility
2011	Commenced commercial manufacturing of SDAs
2013	Attained turnover of INR 500.00mn
2015	Attained turnover of INR 1bn Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of the Company Set up warehousing facility in Netherlands
2017	Set up its Dahej Manufacturing Facility
2018	Set up R&D facility in Vadodara
2019	Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of the Company
2020	Completion of 'Together for Sustainability' audit Conversion of its Ankleshwar Manufacturing Facility to a 'zero liquid effluent discharge facility' Attained total revenue of INR 2bn Increase in manufacturing capacity at its Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines

Source: Company

Considering the wide application of its products, the company serves customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints & coatings, dyes and pigments, personal care and flavour & fragrances industries. As of 31Mar'21, the company manufactured over 154 products, which can be divided into the following four broad categories:

1) Phase Transfer Catalysts (PTCs):

TCPL manufactures phase transfer catalysts (PTCs), which are used for a variety of industrial processes and facilitate the migration of a reactant from one phase into another phase where the reaction occurs, in a heterogeneous multi-phase system. TCPL is the largest producer of PTCs in India and one of the leaders across the globe. It is also among the top 2 manufacturers producing an entire range of PTCs. The company has set up its wholly-owned subsidiaries in North America and Europe as their marketing & distribution arms which would allow it to cater to the demand of the domestic as well as international market. As of 31Mar'21, the company offered 48 products under its PTC product portfolio. PTCs accounted for 47.1%, 41.9%, 28.5% and 27.2% of its revenue from operations, during FY18, FY19, FY20 and FY21, respectively.

TCPL's key products will enable it to gain a larger market share. TCPL's key products, like methyl tributyl ammonium chloride and methyl triocyl ammonium chloride, are expected to post a +3% CAGR globally. Benzyl triethyl ammonium chloride is a lipophilic phase-transfer

catalyst that can be used to catalyse poly condensation reactions and is expected to post a +4% CAGR. Tetra butyl ammonium bromide (TBAB) is used in the pharmaceutical industry. The implementation of rigorous government regulations to reduce the use of hazardous chemicals is also supporting recycling in the global TBAB market, which is expected to post a +5% CAGR.

2) Structure Directing Agents (SDAs):

With extremely few players in the Indian and global market, the company is the largest and only commercial manufacturer of SDA for Zeolites in India. It also enjoys the second largest position globally. The advanced chemistries also make it extremely difficult for new players to enter the market chemistry. With the recent developments in emission control and refining catalyst applications, TCPL's deep knowledge about the SDA for Zeolites market helps it to gain market position.

TCPL's key chemistries and products are gaining importance in the global market. The global production of Tetramethyl Ammonium Hydroxide was valued at around USD 1.2bn in CY19. Having multiple applications, to inhibit nanoparticle aggregation, the Tetramethyl Ammonium Hydroxide market is expected to register a 7% CAGR through CY20-25E with Korea and China dominating the market, however, with just 2-3 players in the domestic market, TCPL stands an opportunity to expand and explore the global market.

Tetra propyl ammonium bromide and Tetra ethyl Ammonium Hydroxide, TCPL's key products are used as reagents in the synthesis of zeolite. TCPL's products are critical in the manufacturing of zeolites as the charge distribution and the size and geometric shape of a template are the causes of including structure-directing agents. This growth in the demand for zeolites as a catalyst is in turn driving the growth of these products. TCPL is the only company, which manages the entire value chain across the globe.

TCPL's SDAs are quaternary salts, which help in the formation of particular channels and pores during the synthesis of zeolites. Zeolites have varied applications including as catalysts and adsorbents. In particular, zeolites - promoted with transition metals such as copper and iron - have been proven to be active for the selective catalytic reduction, which is currently considered as one of the preferred technologies for emission control in automotive applications. New and innovative applications are driving the growth of the zeolite market, in turn driving the quaternary ammonium compounds (QAC) market. As of 31Mar'21, the company offered 47 products under its SDA product portfolio. SDAs accounted for 14.6%, 12.3%, 38.6% and 40.0% of its revenue from operations, during FY18, FY19, FY20 and FY21, respectively.

3) Pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC):

TCPL is among the key players in the specialty chemicals segment, with its range of products finding applications among the high growth segments mentioned above. Engaged in the manufacture of a variety of Disinfectants, Catalysts, Agro and Pharmaceuticals intermediates and other specialty intermediates, TCPL has a good product mix across sectors of Agrochemicals, Pharmaceuticals, Personal care, etc.

Glyme is used in various applications of drug research, battery research, biological research and others. Currently, very few players in India produce this, namely, TCPL, Prasol Chemicals, Sanjay Chemicals, Tolani Chemicals. TCPL is one of the largest producers of Glymes across the globe. It is the largest producer of Glymes in India and third largest in the world. The Global glyme market is estimated to register growth at a rate of 15-17% during CY20-25E; India will contribute significantly to this growth with government initiatives and investments supporting the Pharmaceutical sector generously.


TCPL is best positioned to reap the benefits of the on-going government incentives and initiatives to revive the Agrochemicals and Pharmaceutical API industry and decrease over reliance on Chinese imports. India's continued growth in the both these markets, in particular

through increased exports, are set to directly benefit the country's producers of excipients and intermediates.

TCPL's items under this category are used in the manufacture of various pharmaceutical and agrochemical products as intermediates, disinfectants, catalysts and solvents. In addition, the company manufactures specialty chemicals under this category that are used in dyes & pigments, personal care ingredients, flavour and fragrance sectors. As of 31Mar'21, the company offered 53 products under its PASC product portfolio. PASC accounted for 36.0%, 42.4%, 29.1% and 30.4% respectively, of its revenue from operations, during FY18, FY19, FY20 and FY21, respectively.

4) Electrolyte salts for super capacitor batteries:

TCPL's electrolyte salts are used in the manufacture of super capacitor batteries, which are used in automobile batteries and other batteries. TCPL is the largest producer of organic battery electrolytes for super capacitors in India. As of 31Mar'21, the company offered 6 products under its Electrolyte salts product portfolio. Electrolyte salts for super capacitor batteries accounted for 0.6%, 1.6%, 1.8% and 1.0% respectively, of its revenue from operations, during FY18, FY19, FY20 and FY21, respectively.



Source: Company, JM Financial

Source: Company, JM Financial


Industry overview

Global phase transfer catalyst (PTC) market

Phase-Transfer Catalyst facilitates the migration of a reactant from one phase into another where the reaction occurs. The catalyst functions as a detergent for solubilising the salts into the organic phase. Phase-transfer catalyst offers faster reactions, higher conversions or yields, makes fewer by-products, eliminates the need for expensive or dangerous solvents, eliminates the need for expensive raw materials, and minimises waste problems. Phase-transfer catalysts, like ammonium salts among others have applications in pharmaceuticals and agrochemicals, which is likely to drive this market.

Global PTC market was valued at USD 1.03bn in CY19. During CY19-24E, the global PTC market is projected to expand at a 5.2% CAGR and reach USD 1.3bn by CY24E. Phase transfer catalysts are widely used in green chemistry applications. Therefore, the increasing global focus of the chemical industry on reducing residual waste and reducing the use of organic solvents is boosting the market for catalysts for phase transfer.


With several players across the globe and no substantial market share, the global PTC market is highly fragmented in nature. A few manufacturers operating in the global PTC market are: SACHEM Inc (US), Tokyo Chemical (Japan), Nippon Chemical (Japan), Tatva Chintan Pharma Chem (India), Dishman Group (India), Central Drug House (India), Pacific Organics (India), Otto Chemie (India), Volant-Chem (China), Solvay (Belgium), etc.



Source: Company

India PTC market

Indian PTC market is currently valued at a little over USD 37mn (accounts for ~3.5% of the global PTC market, in 2019). With multiple initiatives from the government favourable for the growth of the Pharmaceutical and Agrochemical industries, India would see a growth in demand for PTCs, of CAGR 6.6%, and reach USD 51.3mn by CY24E, thereby increasing its market share to ~4% by 2024F. The key manufactures in the Indian market are TCPL, Dishman Group, Delta Finochem, Pacific Organics Private Limited, Otto Chemie, TCI Chemicals and a few other smaller players.



Source: Company

The growth of end industries like pharmaceuticals and agrochemicals are driving the development of the PTC market in India. With a few large manufacturers in India, India is keen on exports thereby aiming to improve its market share. The demand for Phase Transfer Catalysts is expected to grow owing to their advantages in realizing faster rate of reactions, achieving better yields or conversions, form a lesser number of by-products, eliminating the requirement for unsafe solvents and minimising concerns associated with waste production. The increase in demand for the adoption of green chemistry in India would also boost the PTC market.


Global Quaternary Ammonium Compounds (Quats) market

Quaternary ammonium compounds are usually used in personal care products, as conditioning agents during the production of the skin, cloth, and hair softeners and also as disinfectants in the food industry. Major applications for QACs are found in detergents due to the rising hygiene awareness among consumers. Growing demand for builders in detergents owing to its enhanced cleaning property is expected to augment market growth. Furthermore, development of the detergents industry is expected to fuel product demand over the forecast period. Due to their high cation-exchange ability as well as to the molecular sieve properties, they have been widely used as adsorbents in separation and purification processes over the last few years.

More recently, zeolites have also been introduced for catalytic emission control, e.g., reducing the emission levels of nitrogen oxides (NOx) from both stationary and mobile sources. In particular, zeolites promoted with transition metals such as copper and iron have been proven to be active for the selective catalytic reduction of NOx by ammonia, which is currently considered as one of the preferred technologies for NOx removal from lean exhaust gases in automotive applications. Areas in which zeolites show strong environmental potential are: reduction of atmospheric NOx, reduction of atmospheric VOC's (including automotive cold start), process improvements in the chemical industry.

The global market for Quaternary Ammonium Compounds (Quats) is expected to post a CAGR of 6.8% from USD 963.7mn in CY19 to USD 1.4bn in CY24E. The growth in hospitalacquired infections, an increase in the geriatric population, growth in the prevalence of chronic disease, and the rise in the number of surgical procedures are fostering the demand for the Quats market. The developing economies are expected to give market players ample growth opportunities.


Fabric softeners, disinfectants, surfactants, antistatic agents, and wood preservation, among others act as quaternary ammonium compounds. The different application of the product is expected in the coming period to increase its demand. In personal care products, quaternary ammonium compounds are typically used as conditioning agents during the manufacture of skin, fabric, and hair softeners and also as a conditioning agent during the manufacture of the skin, cloth, and hair softeners and also as disinfectants in the food industry.



Source: Company Note: the above is inclusive of its use in manufacturing of zeolites as SDAs and further in zeolite catalysts

India Quats market

India represents ~6% of the global Quats market standing at USD 61mn. APAC represents ~28% of the market excluding India. The demand for quaternary ammonium compounds is growing in the Asia Pacific region owing to the increasing disposable income of the people in China, and India, which is increasing the sales of personal care products. India is forecasted to post a CAGR of 7.1% during the forecast period. With a rising concern over health and hygiene in addition to the support from the government in numerous ways to focus on disinfection, the market for QACs in India will see a boom. The market in India is driven by the growing population, economic growth, increasing industrialisation, and infrastructure development.




Source: Company Note: the above is inclusive of its use in manufacturing of zeolites as SDAs and further in zeolite catalysts

Global Pharma & Agro Intermediates and other Specialty Intermediates Market Overview

The global specialty intermediates market stands at USD 115bn in the CY19, and is projected to post a 5.2% CAGR by CY24E and estimated to reach USD 148bn. This growth is primarily driven through the high growth end-use segments such as pharmaceuticals, agrochemicals, paints and coatings, personal care, flavour & fragrances, etc. Some countries such as China and India have been actively catering to export-led demand in the application segments of specialty intermediates, which is making these regions attractive (within Asia Pacific) in intermediates space.

Intermediates refer to the substances that are semi-finished products and used as catalysts. Chemical intermediates are generated during each and every step of the chemical reaction that is meant to change a reactant into a final product. Intermediates come in various forms such as solid, liquid as well as gas. Specialty intermediates are highly consumed in application segments like manufacturing, API, crop protection active ingredients, paints and coatings, detergents, textiles, etc.


More than half of the specialty intermediates market is concentrated in developed regions such as United States, Western European nations, etc. The presence of multinational conglomerates is prominent in these regions and some quantities of specialty intermediates are also exported to high demand centres such as Asia Pacific. Due to a shift in the manufacturing base towards east, APAC holds significant market share in the specialty intermediates market. Further, reagents/reactants, solvents, protective groups and buildings blocks account for around 75% of the market of specialty intermediates across the globe. The remaining 25% comprises of lubricants, catalysts and other chemistries.



Source: Company Note: the above is inclusive of its use in manufacturing of zeolites as SDAs and further in zeolite catalysts

India Specialty Intermediates Market

India specialty intermediates market stands at USD 6.7bn in CY19 projected to record a 10.2% CAGR over the next half decade to reach USD 10.8bn by the year CY24F. India's specialty intermediates market accounts for approximately 5-6% of the global specialty intermediates market. Pharmaceutical intermediates market comprise of more than half of the India specialty intermediates market. Some of the large volume specialty intermediates used in pharmaceutical application are amides, chlorides, organic acids, hydrochlorides, amines, hydroxides, etc. Pharmaceutical and agrochemical segments are expected to grow exponentially in India leading to a growth in the market size of these application segments as well. API and bulk drugs are the key markets for specialty intermediates in India. This market constitutes of >50% of the total India specialty intermediates market (64%).



Source: Company Note: the above is inclusive of its use in manufacturing of zeolites as SDAs and further in zeolite catalysts

Raw materials

The raw materials used by TCPL in its manufacturing process may be categorised as follows: i) tertiary amines; ii) alkyl halides; iii) general solvents; and iv) general and fine chemicals. The cost of materials consumed represented 57.3%, 55.5% and 50.2% in FY19, FY20, and FY21, of its revenue from operations, respectively.

The company's tertiary amines are sourced from both domestic as well as overseas suppliers located in USA, Germany and China. Apart from tertiary amines, the remaining raw materials are primarily sourced from the domestic suppliers in Gujarat and Maharashtra, on a purchase order basis. In FY19, FY20 and FY21, its expenditure on raw materials sourced from domestic suppliers accounted for 73.5%, 44.4% and 54.6%, respectively, of its total expenditure on its raw materials.




Exhibit 30. Raw material cost likely to remain steady at ~48% over FY22-24E

As part of its manufacturing operations, the company requires a steady and abundant supply of power and steam. Its power requirements of its Ankleshwar Manufacturing Facility are met through local state power grid. For its Dahej Manufacturing Facility, the company has entered a power purchase agreement with a private sector power company for the supply of electrical power. The company also maintains diesel generator sets at its manufacturing facilities, as a precaution against any disruption in power supply. The Ankleshwar Manufacturing Facility and Dahej Manufacturing Facility receive water supply from the Gujarat Industrial Development Corporation ("GIDC"). Utility charges accounted for 4.2%, 5.8% and 5.8%, of its total expenses in FY19, FY20, and FY21, respectively.

Source: Company, JM Financial

Manufacturing Facilities


TCPL currently operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat, both of which are strategically located very close to the Hazira port. Over the years, the company has invested in its processes and its manufacturing infrastructure and systems.

TCPL's manufacturing facilities employ various modern machinery and equipment, including reactors, assembly lines, Agitated Nutsche Filter Dryers (ANFDs), centrifuges and Rotary Conical Vacuum Dryers (RCVDs). These equipment's enable its facilities to undertake various chemistry processes, such as, quaternization, methylation, amination, phase transfer reactions, cyclization, halogenation, condensation, and electrolysis.

As part of its eco-friendly and environmentally sustainable initiatives, TCPL has adopted various 'green' chemistry processes, including electrolysis as part of its manufacturing process. Besides the single starting raw material, electrolysis only uses water and electricity to produce the target product. Considering that no additional chemicals are used, this helps ensure that the company does not generate any additional waste or by-products. TCPL has a team of 20 employees at its R&D facility at Vadodara. The team comprises of seven personnel with doctorate degrees in science. TCPL's Promoter, Chintan Shah is responsible for and heads the R&D initiatives of the company.

Further, since the commencement of its dedicated R&D department, its portfolio has grown from one product in 1996 to 154 products as of 31Mar'21. The company believes that its product and process innovations will be key factors going forward and its continued investment in R&D will better prepare it for sustainability and take advantage of any future opportunities.

Over FY19-21, TCPL phase-wise increased its reactor capacity to 280KL in FY21 (from 160KL in FY19) and assembly lines were increased to 17 in FY21 (from 10 in FY19). The company is currently in the process of further expansion at its Dahej facility. Plant testing and commissioning would start from Oct'22 while the commercial production is expected to commence in Nov'22. Hence, we expect the full ramp-up of additional capacities to start from 4QFY23.



Valuation

Due to tightening of environmental norms and further applications, demand for SDAs is likely to get a further boost. Being the only commercial manufacturer out of India and second largest in the world for SDA, we believe TCPL is well placed to benefit from this shift. We initiate coverage on TCPL with a BUY and Mar'23 TP of INR 2,650/share (based on 40X Mar'24E EPS). We believe TCPL's valuation premium (compared with other listed Indian specialty chemicals companies) is justified due to strong entry barriers offered by SDAs.

Exhibit 32. TCPL's peer comparison													
Company	M.Cap		EV/EBITDA			P/E(x)		P/B (x)			ROE (%)		
	(USD Bn)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
Anupam Rasayan	1.1	42.9	31.8	23.4	91.2	49.4	32.3	4.6	4.5	4.0	7.3	9.5	13.0
Clean Science Tech*	2.9	81.2	65.6	50.3	107.2	89.7	69.1	39.4	27.6	19.9	45.0	36.2	33.4
Tatva Chintan*	0.6	40.8	28.0	21.0	80.9	54.3	41.1	25.5	9.9	8.1	36.8	27.0	21.7
Navin Fluorine	2.3	42.1	45.1	29.3	53.0	61.7	41.2	8.3	9.4	7.9	16.9	16.0	20.7
Galaxy Surfactants	1.6	20.4	23.7	20.5	29.9	36.0	30.8	6.9	7.6	6.4	25.5	22.7	22.4
PI Industries	6.4	31.9	36.4	28.1	45.2	53.6	42.4	6.4	7.8	6.8	18.0	15.7	17.1
SRF Ltd	8.7	16.1	25.6	21.8	26.3	41.9	35.4	4.7	8.0	6.7	20.3	20.7	20.4
Aarti Industries	4.9	26.4	30.0	23.7	43.9	46.7	36.3	6.6	6.9	6.0	16.2	17.9	17.4
Atul Ltd	3.8	21.8	25.4	22.1	31.8	37.7	32.5	5.5	6.5	5.4	18.9	18.2	17.6
Fine Organic	1.4	34.1	38.5	29.0	58.2	58.7	42.9	9.6	11.8	9.9	17.8	22.3	25.0
Vinati Organics	2.8	40.3	42.4	32.6	53.4	57.5	43.2	9.3	11.3	9.2	19.1	21.5	23.6
Balaji Amines	1.8	15.5	28.0	22.4	23.9	41.5	32.8	6.4	12.2	9.6	30.7	28.9	27.9
Alkyl Amines	2.6	26.8	41.0	35.6	39.4	62.6	51.6	14.7	19.4	15.4	44.4	34.4	32.7

Source: Bloomberg, JM Financial, Note: *based on JMFe due to limited Bloomberg consensus estimates

Key risks

- Failure to comply with customer's quality requirements and technical specifications: TCPL primarily specialises in manufacture and supply of specialty chemicals. Given the nature of its products, its customers have high standards for product quality as well as delivery schedules. Adherence to quality standards is a critical factor in its manufacturing process as any defects in the products manufactured by the company or failure to comply with the technical specifications of its customers may lead to cancellation of the orders placed by its customers.
- Dependency on limited suppliers for the supply of certain raw materials: TCPL currently relies on limited suppliers to provide certain raw materials. The company does not have long-term agreements with such suppliers, and the loss of one or more of such suppliers or a reduction in the amount of raw materials the company obtains from them could have an adverse effect on its business, results of operations, financial condition and cash flows. Its reliance on a select group of suppliers may also constrain its ability to negotiate its arrangements, which may have an impact on its profit margins and financial performance. Its suppliers could fail to meet their obligations, which may have an adverse impact on its business and results of operations. Further, there can be no assurance that strong demand, capacity limitations or other problems experienced by its suppliers will not result in occasional shortages or delays in their supply of raw materials.
- Increase in the cost of raw materials could have a material adverse effect on results of operations and financial conditions: TCPL's primary raw materials include tertiary amines, alkyl halides, general solvents and other general and fine chemicals. Cost of materials consumed represented 54.6%, 57.3%, 55.5%, and 50.2% of revenue from operations for FY18, FY19, FY20, and FY21, respectively. The price of its product is generally fixed at the time of purchase order and therefore may not be able to pass on an increase in cost of raw material to its customers.
- Foreign operations and exchange fluctuation risk: TCPL exports most of its products to various countries, including the USA, China, Germany, Japan, South Africa and the UK. Exports of its products accounted for 64.9%, 69.6%, 76.7% and 70.6% of its revenue from operations, during FY18, FY19, FY20, and FY21, respectively. As a result of its existing and expanding international operations, the company is subject to risks inherent to establishing and conducting operations on an international scale, including: fluctuation

in the exchange rate, ability to obtain the necessary approval from regulatory authorities, etc.

- Customer concentration risk: While TCPL typically has long-term relationships with its customers, the company does not have long-term agreements with them. The success of its business is accordingly significantly dependent on the company maintaining good relationships with its customers and suppliers. While the company has a number of customers, it is dependent on a limited number of customers for a significant portion of its revenue. 47%, 58.4% and 60%, of its revenue from operations were derived from its top ten customers, during FY19, FY20, and FY21, respectively.
- High dependency on R&D and introduction of innovative products: In order to remain competitive, TCPL needs to develop, test and manufacture new products, which must meet regulatory standards and receive requisite regulatory approvals. To accomplish this, the company commits substantial effort, funds and other resources towards its R&D activities and the company has set-up a dedicated R&D centre in Vadodara, Gujarat. For FY19, FY20, and FY21, its total expenditure for R&D activities was INR 39.39mn, INR 39.94mn, INR 51.14mn, respectively, representing 1.9%, 1.5% and 1.7% of its revenue from operations, respectively. Of which, capital expenditure towards R&D was INR 19.95mn, INR 13.62mn, INR 26.47mn, and INR 89.46mn, during FY19, FY20, and FY21, respectively. However, the company's on-going investments in R&D for new products and processes may result in higher costs without a proportionate increase in revenues. Delays in any part of the process, its inability to obtain necessary regulatory approvals for its products or failure of a product could adversely affect its business.

Board of Directors and Key Managerial Personnel

Board of Directors

- Chintan Nitinkumar Shah is the Managing Director on TCPL's Board. He holds a bachelor's degree in engineering, with a specialisation in computer science from the Maharaja Sayajirao University of Baroda. He is responsible for, among others, business development and finance and information services, in the company. He has over 24 years of experience.
- Ajaykumar Mansukhlal Patel is a Whole Time Director on TCPL's Board. He holds a bachelor's degree in engineering, with a specialisation in chemical engineering from the Maharaja Sayajirao University of Baroda. He is responsible for, among others, project engineering and the development and implementation of new technology, in the company. He has over 26 years of experience. He was previously associated with Sun Pharmaceutical Industries Limited as officer chemical engineering.
- Shekhar Rasiklal Somani is a Whole Time Director on TCPL's Board. He holds a bachelor's degree in pharmacy from the Maharaja Sayajirao University of Baroda. He is responsible for business development, production controlling, quality, and supply chain management, in the company. He has over 24 years of experience.
- Manher Chimanlal Desai is an Independent Director on TCPL's Board. He holds a bachelor's degree in science, a master's degree in science (specialising in organic chemistry), and a doctorate in science from the University of Mumbai. He has previously been associated with Indian Dyestuff Industries Limited, Metrochem Industries Limited, Alaknanda Organics Limited, and Heubach Colour Private Limited.
- Subhash Ambubhai Patel is an Independent Director on TCPL's Board. He holds a bachelor's degree in commerce from The Maharaja Sayajirao University of Baroda. He is a fellow of the Institute of Chartered Accountants of India. He has over 33 years of experience in accountancy and audit. He is currently a partner at M/s S.A. Patel & Co., Chartered Accountants.
- Avani Rajesh Umatt is an Independent Director on TCPL's Board. She holds a bachelor's degree in science and a master's degree in science (specialising in applied chemistry) from The Maharaja Sayajirao University of Baroda and a doctorate in philosophy for chemistry from the Sardar Patel University. She also holds a diploma in performing arts in Kathak from The Maharaja Sayajirao University of Baroda and a bachelor's degree in music from the Gandharva Mahavidyalaya. She has over 19 years of experience in research and academia. She is currently associated with TeamLease Skills University as Associate Professor, Dean Academics HOD, Department of Health, Life and Applied Sciences. She has previously been associated with the Sardar Patel University, Indiamalt Private Limited, Bharatiya Vidya Bhavan's Sardar Patel College of Engineering, The Maharaja Sayajirao University of Baroda, Global Discovery Academy and GSFC University.

Key Management Personnel

- Apurva Dubey is the Company Secretary and Compliance Officer of the company. She has been associated with the company since 25Feb'21. She is responsible for the company secretarial and compliance work in the company. She holds a bachelor's degree in management studies from the University of Mumbai and a bachelor's degree in law from The Maharaja Sayajirao University of Baroda. She is also an associate member of the ICSI. She has experience of over four years and has been previously associated with Pan Drugs Limited, BTW Atlanta Transformers India Private Limited, and Haver and Boecker India Private Limited.
- Harish Laljibhai Patel is the General Manager operations of the company. He has been associated with the Company since 12Oct'07. He is responsible for production planning, quality maintenance of products, and safety of employees in the company. He holds a

bachelor's degree in science from Gujarat University. He has previously been associated with Champa Purie-Chem Industries.

- Ajay Singh Rawat is the Head –General Manager R&D of the company. He has been associated with the company since 5Jul'19. He is responsible for development of new molecules as per management requirement and preparation of the literature search report in the company. He holds a bachelor's degree in science and a master's degree in science (specialising in chemistry) from the Doctor Harisingh Gour Vishwavidyalaya, Sagar and he also holds a diploma in pharmaceutical production management from the Institute of Pharmaceutical Education and Research (Pune) Private Limited and a post graduate diploma in patent management from the Academy of Intellectual Property Studies. He has previously been associated with IPCA Laboratories Limited, Sterling Biotech Limited, Unichem Laboratories Limited, and Merck Development Centre Private Limited.
- Rakesh Poonia is the Assistant General Manager Commercial of the company. He has been associated with the company since 17Nov'06. He is responsible for commercial, purchase, and liaisoning activities in the company. He holds a bachelor's degree in arts from the University of Rajasthan and a post graduate diploma in export import management from the Indian Institute of Export. He has previously been associated with Shree Colorsperse Private Limited, and Heubach Colour Private Limited.
- Niteshkumar M Prajapati is the Assistant General Manager HR and Admin of the Company. He has been associated with the Company since 21Nov' 15. He is responsible for human resource management, administration, and industrial relations in the company. He holds a bachelor's degree in science from the South Gujarat University, a bachelor's degree in law from the Veer Narmad South Gujarat University, post-graduate diploma in industrial relations and personnel management from Bharatiya Vidya Bhavan's Rajendra Prasad Institute of Communication and Management, and the Maharashtra state certificate in information technology from the Government of Maharashtra. He has previously been associated with Kiran Gems Private Limited, Gujarat Polyfilms Private Limited, Janak Healthcare Private Limited, Larsen & Toubro Limited, and N.J. Gems.

Promoters

The Promoters of the company are Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Shekhar Rasiklal Somani.

- Ajaykumar Mansukhlal Patel, aged 49 years, is one of TCPL's promoters and is also a whole time director on its board. He holds a bachelor's degree in engineering, with a specialisation in chemical engineering from the Maharaja Sayajirao University of Baroda. He is responsible for, among others, project engineering and the development and implementation of new technology, in the company.
- Chintan Nitinkumar Shah, aged 47 years, is one of TCPL's promoters and is also the Managing Director on its board. He holds a bachelor's degree in engineering, with a specialisation in computer science from the Maharaja Sayajirao University of Baroda. He is responsible for, among others, project engineering and the development and implementation of new technology, in the company.
- Shekhar Rasiklal Somani, aged 47 years, is one of TCPL's promoters and is also a whole time director on its board. He holds a bachelor's degree in pharmacy from the Maharaja Sayajirao University of Baroda. He is responsible for business development, production controlling, quality, and supply chain management, in the company.

Financial Tables (Consolidated)

Income Statement				(INR mn)
Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
Net Sales	2,632	3,004	4,182	5,617	7,151
Sales Growth	27.6%	14.1%	39.2%	34.3%	27.3%
Other Operating Income	0	0	0	0	0
Total Revenue	2,632	3,004	4,182	5,617	7,151
Cost of Goods Sold/Op. Exp	1,328	1,494	2,024	2,713	3,454
Personnel Cost	205	241	287	359	434
Other Expenses	550	611	855	1,053	1,305
EBITDA	550	657	1,015	1,492	1,957
EBITDA Margin	20.9%	21.9%	24.3%	26.6%	27.4%
EBITDA Growth	62.6%	19.6%	54.5%	46.9%	31.2%
Depn. & Amort.	48	67	72	123	173
EBIT	502	590	943	1,369	1,785
Other Income	14	59	74	68	69
Finance Cost	39	42	47	44	45
PBT before Excep. & Forex	476	607	970	1,393	1,809
Excep. & Forex Inc./Loss(-)	0	0	0	0	0
PBT	476	607	970	1,393	1,809
Taxes	98	84	111	258	333
Extraordinary Inc./Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	0	0	0	0	0
Reported Net Profit	378	523	859	1,136	1,476
Adjusted Net Profit	378	523	859	1,136	1,476
Net Margin	14.4%	17.4%	20.6%	20.2%	20.6%
Diluted Share Cap. (mn)	20.1	20.1	22.2	22.2	22.2
Diluted EPS (INR)	18.8	26.0	38.8	51.2	66.6
Diluted EPS Growth	90.9%	38.3%	49.0%	32.1%	30.0%
Total Dividend + Tax	0	2	2	2	2
Dividend Per Share (INR)	0.0	0.1	0.1	0.1	0.1

Balance Sheet				(INR mn)
Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
Shareholders' Fund	1,177	1,660	4,703	5,751	7,114
Share Capital	80	201	222	222	222
Reserves & Surplus	1,097	1,459	4,481	5,530	6,892
Preference Share Capital	0	0	0	0	0
Minority Interest	0	0	0	0	0
Total Loans	792	761	1,231	1,401	1,921
Def. Tax Liab. / Assets (-)	45	21	21	21	21
Total - Equity & Liab.	2,013	2,441	5,954	7,173	9,055
Net Fixed Assets	1,161	1,303	2,134	2,915	2,792
Gross Fixed Assets	1,219	1,376	1,475	3,232	3,282
Intangible Assets	3	4	4	4	4
Less: Depn. & Amort.	111	176	248	370	543
Capital WIP	49	98	904	50	50
Investments	7	9	9	9	g
Current Assets	1,322	1,837	4,445	5,020	7,172
Inventories	636	720	1,003	1,347	1,715
Sundry Debtors	496	907	1,263	1,697	2,160
Cash & Bank Balances	102	45	2,033	1,831	3,152
Loans & Advances	17	19	0	0	C
Other Current Assets	72	145	145	145	145
Current Liab. & Prov.	476	707	633	771	918
Current Liabilities	316	489	415	553	700
Provisions & Others	160	218	218	218	218
Net Current Assets	846	1,130	3,812	4,249	6,254
Total – Assets	2,014	2,441	5,954	7,173	9,055

Source: Company, JM Financial

Source: Company, JM Financial

Cash Flow Statement (INR mn)					
Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
Profit before Tax	476	607	970	1,393	1,809
Depn. & Amort.	48	67	72	123	173
Net Interest Exp. / Inc. (-)	31	42	47	44	45
Inc (-) / Dec in WCap.	-226	-378	-693	-640	-684
Others	6	3	0	0	0
Taxes Paid	-82	-98	-111	-258	-333
Operating Cash Flow	253	243	285	662	1,010
Capex	-482	-210	-904	-904	-50
Free Cash Flow	-229	33	-618	-242	960
Inc (-) / Dec in Investments	74	2	0	0	0
Others	5	-3	0	0	0
Investing Cash Flow	-402	-210	-904	-904	-50
Inc / Dec (-) in Capital	0	121	2,250	0	0
Dividend + Tax thereon	0	0	0	0	0
Inc / Dec (-) in Loans	135	-4	470	170	520
Others	-36	-204	-113	-131	-159
Financing Cash Flow	100	-88	2,607	39	361
Inc / Dec (-) in Cash	-49	-55	1,988	-203	1,321
Opening Cash Balance	157	108	53	2,042	1,839
Closing Cash Balance	108	53	2,042	1,839	3,160

Dupont Analysis					
Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
Net Margin	14.4%	17.4%	20.6%	20.2%	20.6%
Asset Turnover (x)	1.5	1.3	1.0	0.9	0.9
Leverage Factor (x)	1.8	1.6	1.3	1.3	1.3
RoE	38.3%	36.8%	27.0%	21.7%	22.9%

Y/E March	FY20A	FY21A	FY22E	FY23E	FY24E
BV/Share (INR)	58.6	82.6	212.2	259.5	320.9
ROIC	24.8%	24.0%	26.7%	24.2%	26.0%
ROE	38.3%	36.8%	27.0%	21.7%	22.9%
Net Debt/Equity (x)	0.6	0.4	-0.2	-0.1	-0.2
P/E (x)	111.9	80.9	54.3	41.1	31.6
P/B (x)	35.9	25.5	9.9	8.1	6.6
EV/EBITDA (x)	77.9	65.2	40.7	27.9	20.9
EV/Sales (x)	16.3	14.3	9.9	7.4	5.7
Debtor days	69	110	110	110	110
Inventory days	88	88	88	88	88
Creditor days	55	74	46	48	48

Source: Company, JM Financial

APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

 Member of BSE Ltd., National Stock Exchange of India Ltd. and Metropolitan Stock Exchange of India Ltd. SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst – INH000000610
Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.
Board: +9122 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com Compliance Officer: Mr. Sunny Shah | Tel: +91 22 6630 3383 | Email: sunny.shah@jmfl.com

Definition of	Definition of ratings			
Rating	Meaning			
Buy	Total expected returns of more than 10% for large-cap stocks* and REITs and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.			
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for large-cap* stocks and REITs and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.			
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.			

* Large-cap stocks refer to securities with market capitalisation in excess of INR200bn. REIT refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE), National Stock Exchange of India Ltd. (NSE) and Metropolitan Stock Exchange of India Ltd. (MSEI). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and members of their household are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This

report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Persons who receive this report from JM Financial Singapore Pte Ltd may contact Mr. Ruchir Jhunjhunwala (ruchir.jhunjhunwala@jmfl.com) on +65 6422 1888 in respect of any matters arising from, or in connection with, this report.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

JM Financial Institutional Securities only accepts orders from major U.S. institutional investors. Pursuant to its agreement with JM Financial Institutional Securities, JM Financial Securities effects the transactions for major U.S. institutional investors. Major U.S. institutional investors may place orders with JM Financial Institutional Securities directly, or through JM Financial Securities, in the securities discussed in this research report.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.